Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care.
Djebbari F, Panitsas F, Eyre TA, Prodger C, Davies F, Burton K, Khera A, Vallance G, Moore S, Kothari J, Peniket A, Ramasamy K. Djebbari F, et al. Among authors: prodger c. Haematologica. 2020 Sep 1;105(9):e474-479. doi: 10.3324/haematol.2019.240762. Haematologica. 2020. PMID: 33054067 Free PMC article. No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 31919073
Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients.
Rampotas A, Djebbari F, Panitsas F, Lees C, Tsagkaraki I, Gomes AR, Prideaux S, Chen L, Prodger C, Khera A, Gray N, Ellis L, Sangha G, Lim WY, Eyre TA, Moore S, Ramasamy K, Kothari J. Rampotas A, et al. Among authors: prodger c. Eur J Haematol. 2021 Apr;106(4):563-573. doi: 10.1111/ejh.13588. Epub 2021 Feb 5. Eur J Haematol. 2021. PMID: 33496996
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F, Rampotas A, Panitsas F, Lim WY, Lees C, Tsagkaraki I, Gomes AR, Prideaux S, Chen L, Prodger C, Khera A, Gray N, Ellis L, Sangha G, Eyre TA, Moore S, Kothari J, Ramasamy K. Djebbari F, et al. Among authors: prodger c. PLoS One. 2022 Jan 11;17(1):e0262388. doi: 10.1371/journal.pone.0262388. eCollection 2022. PLoS One. 2022. PMID: 35015781 Free PMC article.
Platelet transfusion: Alloimmunization and refractoriness.
Prodger CF, Rampotas A, Estcourt LJ, Stanworth SJ, Murphy MF. Prodger CF, et al. Semin Hematol. 2020 Apr;57(2):92-99. doi: 10.1053/j.seminhematol.2019.10.001. Epub 2019 Nov 8. Semin Hematol. 2020. PMID: 32892848 Review.
Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.
Poynton E, Chernucha E, Day J, Prodger C, Hopkins D, Rakesh P, O'Neill T, Thakrar N, Akarca A, Jamal E, Ali A, Kirkwood AA, Pomplun S, Marafioti T, Calaminici M, Greaves P, Chaganti S, McKay P, Smith J, Eyre TA, Martinez-Calle N, Cwynarski K, Fox CP, Okosun J. Poynton E, et al. Among authors: prodger c. Blood Adv. 2024 Apr 9;8(7):1772-1775. doi: 10.1182/bloodadvances.2023011426. Blood Adv. 2024. PMID: 38039509 Free PMC article. No abstract available.
A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications.
El-Sharkawi D, Sud A, Prodger C, Khwaja J, Shotton R, Hanley B, Peacock V, Peng YY, Arasaretnam A, Sharma S, Aldridge F, Sharma B, Wotherspoon A, Cheung B, De Lord C, Johnston R, Kassam S, Pettengel R, Linton K, Greaves P, Cook L, Naresh KN, Cwynarski K, Eyre TA, Chau I, Cunningham D, Iyengar S. El-Sharkawi D, et al. Among authors: prodger c. Blood Cancer J. 2023 Apr 18;13(1):54. doi: 10.1038/s41408-023-00827-5. Blood Cancer J. 2023. PMID: 37072385 Free PMC article. No abstract available.
11 results